---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-049263"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:42:31.303517+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024

## Summary
- FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.
- Cash at Dec 31, 2023: $340.5M; proforma cash after Feb 2024 $202M upsized offering ~$500M.
- Phase 3 BROOKLYN topline in HeFH expected 3Q2024; BROADWAY in ASCVD expected 4Q2024.
- PREVAIL CVOT enrollment to complete 1Q2024; topline data expected 2026. TANDEM FDC trial initiation 1Q2024 with data 1Q2025.
- Appointed William H. Lewis as Board Chair; Phase 2 data showed significant LDL-C lowering with placebo-like safety.

## SEC filing metadata
- accession: 0001193125-24-049263
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/0001193125-24-049263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/d772021d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-049263
- JSON: https://secwatch.observer/filing/0001193125-24-049263.json
- Plain text: https://secwatch.observer/filing/0001193125-24-049263.txt

## Key facts
- Earnings Releases
  NewAmsterdam Pharma Co N.V. reported financial results for the full year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Result: reported results
  source text: NewAmsterdam Pharma Company N.V. (the "Company") issued a press release announcing corporate updates and its financial results for the full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/0001193125-24-049263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.